Ac immune s.a. (ACIU) 2025Q3 financial report shows revenue of 939K CHF, with a YoY growth rate of -96.32%. This clearly indicates that Ac immune s.a. (ACIU) is facing severe revenue challenges and a significant deterioration. To better understand the business situation, investors are advised to look beyond the revenue YoY, and closely examine trends in net profit, operating profit, and gross margin. In addition, leveraging third-party data such as Growin AI Value Analysis will provide a more comprehensive assessment of the operational pressure and potential financial risks faced by Ac immune s.a. (ACIU).